Tags

Type your tag names separated by a space and hit enter

Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial.
Arthritis Rheum. 2009 Feb; 60(2):524-33.AR

Abstract

OBJECTIVE

To assess the long-term effects of chondroitins 4 and 6 sulfate (CS) on the radiographic progression of, and symptom changes associated with, knee osteoarthritis (OA).

METHODS

We performed an international, randomized, double-blind, placebo-controlled trial in which 622 patients with knee OA were randomly assigned to receive either 800 mg CS (n = 309 patients) or placebo (n = 313 patients) once daily for 2 years. Radiographs of the target knee, using the Lyon schuss view, were obtained at the time of enrollment and at 12, 18, and 24 months. The minimum joint space width (JSW) of the medial compartment of the tibiofemoral joint was assessed by digital image analysis. The primary outcome was the loss in minimum JSW over 2 years.

RESULTS

The intent-to-treat analysis demonstrated a significant reduction (P < 0.0001) in minimum JSW loss in the CS group (mean +/- SEM -0.07 +/- 0.03 mm) as compared with the placebo group (-0.31 +/- 0.04 mm). The percentage of patients with radiographic progression > or =0.25 mm was significantly reduced in the CS group compared with the placebo group (28% versus 41% [P < 0.0005]; relative risk reduction 33% [95% confidence interval 16-46%]). The number of patients needed to treat was 8 (95% confidence interval 5-17). Pain improved significantly faster in the CS group than in the placebo group (P < 0.01). There were no differences in safety between groups.

CONCLUSION

The long-term combined structure-modifying and symptom-modifying effects of CS suggest that it could be a disease-modifying agent in patients with knee OA.

Authors+Show Affiliations

University of Paris Descartes, and Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris, France. andre.kahan@cch.aphp.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19180484

Citation

Kahan, André, et al. "Long-term Effects of Chondroitins 4 and 6 Sulfate On Knee Osteoarthritis: the Study On Osteoarthritis Progression Prevention, a Two-year, Randomized, Double-blind, Placebo-controlled Trial." Arthritis and Rheumatism, vol. 60, no. 2, 2009, pp. 524-33.
Kahan A, Uebelhart D, De Vathaire F, et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60(2):524-33.
Kahan, A., Uebelhart, D., De Vathaire, F., Delmas, P. D., & Reginster, J. Y. (2009). Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism, 60(2), 524-33. https://doi.org/10.1002/art.24255
Kahan A, et al. Long-term Effects of Chondroitins 4 and 6 Sulfate On Knee Osteoarthritis: the Study On Osteoarthritis Progression Prevention, a Two-year, Randomized, Double-blind, Placebo-controlled Trial. Arthritis Rheum. 2009;60(2):524-33. PubMed PMID: 19180484.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. AU - Kahan,André, AU - Uebelhart,Daniel, AU - De Vathaire,Florent, AU - Delmas,Pierre D, AU - Reginster,Jean-Yves, PY - 2009/1/31/entrez PY - 2009/1/31/pubmed PY - 2009/4/2/medline SP - 524 EP - 33 JF - Arthritis and rheumatism JO - Arthritis Rheum. VL - 60 IS - 2 N2 - OBJECTIVE: To assess the long-term effects of chondroitins 4 and 6 sulfate (CS) on the radiographic progression of, and symptom changes associated with, knee osteoarthritis (OA). METHODS: We performed an international, randomized, double-blind, placebo-controlled trial in which 622 patients with knee OA were randomly assigned to receive either 800 mg CS (n = 309 patients) or placebo (n = 313 patients) once daily for 2 years. Radiographs of the target knee, using the Lyon schuss view, were obtained at the time of enrollment and at 12, 18, and 24 months. The minimum joint space width (JSW) of the medial compartment of the tibiofemoral joint was assessed by digital image analysis. The primary outcome was the loss in minimum JSW over 2 years. RESULTS: The intent-to-treat analysis demonstrated a significant reduction (P < 0.0001) in minimum JSW loss in the CS group (mean +/- SEM -0.07 +/- 0.03 mm) as compared with the placebo group (-0.31 +/- 0.04 mm). The percentage of patients with radiographic progression > or =0.25 mm was significantly reduced in the CS group compared with the placebo group (28% versus 41% [P < 0.0005]; relative risk reduction 33% [95% confidence interval 16-46%]). The number of patients needed to treat was 8 (95% confidence interval 5-17). Pain improved significantly faster in the CS group than in the placebo group (P < 0.01). There were no differences in safety between groups. CONCLUSION: The long-term combined structure-modifying and symptom-modifying effects of CS suggest that it could be a disease-modifying agent in patients with knee OA. SN - 0004-3591 UR - https://www.unboundmedicine.com/medline/citation/19180484/Long_term_effects_of_chondroitins_4_and_6_sulfate_on_knee_osteoarthritis:_the_study_on_osteoarthritis_progression_prevention_a_two_year_randomized_double_blind_placebo_controlled_trial_ L2 - https://doi.org/10.1002/art.24255 DB - PRIME DP - Unbound Medicine ER -